Objective: Gastric cancer (GC) is one of the most important upper gastrointestinal malignancies worldwide. Anti-tumor effect of PD-1/PD-L1 inhibitor alone is insufficient, furthermore its combination chemotherapy provides a new direction. To analyze the effectiveness and safety of combination therapy of PD-1/PD-L1 inhibitor combined with CHEMO in regimens of advanced gastric carcinoma (GC). Chinese and English databases were searched to collect clinical randomized controlled trials (RCTs) of PD-1/PD-L1 inhibitors combined with CHEMO in therapy of advanced carcinoma GC/ gastroesophageal junction cancer (GEJC). Combined group ORR (OR=2.63, 95%CI: 1.47~4.68) and DCR (OR=2.42, 95%CI: 1.07~5.51) higher than the control group, FPS (HR=0.71, 95%CI: 0.65~0.77) and OS (HR=0.80, 95%CI: 0.73~0.86) showed a significantly better condition than control group. The occurrence rate of grade 3-5 untoward effects in the combination group showed a higher data than control group, OR=1.24 (95CI: 1.03, 1.49). PD-1/PD-L1 inhibitor combined with CHEMO can promote the treatment effect in advanced GC and build up the medical forecast of patients, but it can increase the incidence of serious adverse reactions.
Authors: Sakarie Mustafe Hidig, Chao Li
DOI: https://doi.org/10.26855/ijcemr.2022.10.021
Publish Year: 2022
